Having at least one potentially clinically significant drug-drug interaction was associated with a 28% higher hazard of cardiovascular death (HR 1.28) in older adults with atrial fibrillation.
Observational (n=192,716)
Does exposure to potentially clinically significant drug-drug interactions increase the risk of adverse clinical outcomes in older adults with atrial fibrillation and multimorbidity?
Potentially clinically significant drug-drug interactions are highly prevalent (37.5%) in older adults with atrial fibrillation and multimorbidity, and are associated with an increased hazard of all-cause and cardiovascular mortality.
Effect estimate: HR 1.28 (95% CI 1.24-1.32)
Absolute Event Rate: 7.3% vs 4.19%
Potentially clinically significant DDIs were prevalent in older adults with AF and multimorbidity, with adverse clinical implications. Identifying these high-risk groups is essential for preventive strategies and effective clinical management.
Amrouch et al. (Thu,) conducted a observational in Atrial fibrillation and multimorbidity (n=192,716). Potentially clinically significant drug-drug interactions (≥ 1 DDI) vs. No potentially clinically significant drug-drug interactions was evaluated on Cardiovascular death (HR 1.28, 95% CI 1.24-1.32). Having at least one potentially clinically significant drug-drug interaction was associated with a 28% higher hazard of cardiovascular death (HR 1.28) in older adults with atrial fibrillation.